Compare Cassava Sciences Inc (FLNA) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs MasTec Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while MasTec Inc trades at $339.22 (market cap $28.27B). The key difference: MasTec Inc is far larger — about 532× Cassava Sciences Inc's market cap, and MasTec Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MTZ | |
|---|---|---|
Market Cap | $53.14M | $28.27B |
Sector | Health | Technology |
52-Week High | $4.64 | $437.51 |
52-Week Low | $1.09 | $172.51 |
Enterprise Value | -$33.43M | $31.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
MasTec (MTZ) trades at $336.22, down 7.91% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.39, and holds a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of The Superior Group to expand AI data center infrastructure capabilities, signaling strategic growth in high-demand markets.
Outlook remains positive driven by infrastructure spending and AI demand, with a consensus price target of $481.77 implying 43% upside. Risks include integration challenges from acquisitions and elevated valuation multiples. Analyst consensus is strongly bullish with 89% buy ratings, supporting long-term growth prospects amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
